Richard A. Morgan

Richard A. Morgan's AcademicInfluence.com Rankings

Richard A. Morgan

Engineering

#5947

World Rank

#7235

Historical Rank

Biomedical Engineering

#485

World Rank

#495

Historical Rank

engineering Degrees

Richard A. Morgan

Philosophy

#8155

World Rank

#11481

Historical Rank

Logic

#5185

World Rank

#6564

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Richard A. Morgan's Degrees

Doctorate Medicine Harvard University

Why Is Richard A. Morgan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard A. Morgan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) (2575)
Genomic analyses identify molecular subtypes of pancreatic cancer (2016) (2343)
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. (2010) (2053)
Whole genomes redefine the mutational landscape of pancreatic cancer (2015) (1983)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) (1752)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008) (1522)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) (1449)
T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years (1995) (1412)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. (2009) (1338)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. (2012) (1306)
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. (1990) (1226)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010) (1174)
Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems (2001) (1089)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy (2013) (943)
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation (1993) (855)
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019) (840)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (2014) (592)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. (2011) (547)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013) (466)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors (2012) (430)
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. (2006) (428)
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. (2011) (349)
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. (2007) (335)
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions (2008) (321)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor (2009) (314)
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 (2006) (303)
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines (1992) (301)
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. (2011) (299)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia (2013) (294)
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2012) (287)
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. (2012) (280)
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 (2009) (275)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. (2011) (272)
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. (2006) (269)
High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. (1995) (266)
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens (2003) (259)
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma (2015) (255)
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss (2013) (246)
dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. (2000) (244)
Treating cancer with genetically engineered T cells. (2011) (237)
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. (2005) (237)
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. (2010) (234)
Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (233)
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. (2011) (229)
Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors (2012) (220)
Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. (1992) (217)
Safety issues related to retroviral-mediated gene transfer in humans. (1991) (211)
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. (2010) (209)
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1 (2007) (201)
Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines (2005) (199)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma (2019) (180)
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition (2008) (172)
Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. (1990) (160)
Hypermutation In Pancreatic Cancer. (2017) (160)
A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer (2011) (157)
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. (2014) (144)
Lymphocytes as cellular vehicles for gene therapy in mouse and man. (1991) (136)
Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR (2005) (133)
Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. (2003) (131)
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. (2008) (129)
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. (2017) (127)
Toxicity of a first-generation adenoviral vector in rhesus macaques. (2002) (127)
Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials (2010) (126)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. (2018) (126)
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. (2007) (124)
Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. (1999) (122)
Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. (2002) (119)
Gene Therapy for Infectious Diseases (1998) (119)
The Shedding of CD62L (L-Selectin) Regulates the Acquisition of Lytic Activity in Human Tumor Reactive T Lymphocytes (2011) (110)
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. (2007) (109)
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry (2012) (107)
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells (2014) (107)
The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion (2002) (104)
Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1 (2005) (99)
Adoptive Cell Therapy: Genetic Modification to Redirect Effector Cell Specificity (2010) (98)
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. (2011) (97)
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. (2007) (97)
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression (2009) (96)
Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. (1998) (96)
Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. (1990) (95)
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity (2009) (93)
Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. (2000) (92)
Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference. (2002) (92)
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity (2015) (91)
Treatment of Severe Combined Immunodeficiency Disease (SCID) due to Adenosine Deaminase Deficiency with CD34+ Selected Autologous Peripheral Blood Cells Transduced with a Human ADA Gene (Amendment). National Institutes of Health (1993) (90)
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails (2013) (90)
Analysis of the functional and host range-determining regions of the murine ectropic and amphotropic retrovirus envelope proteins (1993) (89)
Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses. (2016) (89)
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy (2012) (88)
Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. (2000) (87)
Development of an Avian Leukosis-Sarcoma Virus Subgroup A Pseudotyped Lentiviral Vector (2001) (87)
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. (2002) (86)
Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies (2011) (85)
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. (2013) (84)
Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase (2010) (82)
Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes (1995) (81)
Neuroanatomical localization and quantification of amyloid precursor protein mRNA by in situ hybridization in the brains of normal, aneuploid, and lesioned mice. (1988) (81)
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. (2013) (80)
Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. (1995) (79)
No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. (1991) (78)
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. (1995) (78)
Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy (2017) (77)
T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model (2008) (75)
Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition (2010) (73)
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. (2010) (73)
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. (2015) (73)
Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. (2009) (72)
Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. (1996) (71)
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. (2005) (69)
Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. (2012) (69)
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. (2009) (66)
bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. (2018) (63)
A simple and reliable method for screening retroviral producer clones without selectable markers. (1997) (63)
Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. (2004) (63)
Collapse of the tumor stroma is triggered by IL-12 induction of Fas. (2013) (62)
Evaluation of recombinant alphaviruses as vectors in gene therapy (2000) (60)
Development of Improved Adenosine Deaminase Retroviral Vectors (1998) (59)
Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy (2013) (56)
The deubiquitinase USP 9 X suppresses pancreatic ductal adenocarcinoma (2012) (53)
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. (2017) (53)
B cell regulation of anti-tumor immune response (2013) (53)
Infection of human cells with murine amphotropic replication-competent retroviruses. (1993) (51)
Gut epithelial cells as targets for gene therapy of hemophilia. (1997) (51)
Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. (1996) (51)
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? (2012) (50)
In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. (1990) (50)
Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. (1990) (46)
Human tumor xenografts: the good, the bad, and the ugly. (2012) (45)
The rhesus macaque as an animal model for hemophilia B gene therapy. (1999) (45)
Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes (1998) (45)
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (45)
CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis (2012) (45)
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines (2021) (44)
Expression of a foreign gene in cats reconstituted with retroviral vector infected autologous bone marrow. (1991) (44)
Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated Cells (2008) (41)
Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. (1996) (40)
Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. (2000) (40)
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. (2008) (39)
Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element (2000) (37)
Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. (1994) (37)
A Simplified Method for the Clinical-scale Generation of Central Memory-like CD8+ T Cells After Transduction With Lentiviral Vectors Encoding Antitumor Antigen T-cell Receptors (2010) (36)
Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. (1994) (36)
Genetic modification of T cells. (2014) (36)
Efficient in vivo marking of primary CD4+ T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. (1997) (35)
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion (2010) (35)
Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. (1994) (33)
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. (2019) (32)
Evaluation of &ggr;-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application (2012) (31)
Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication by HIV-1-Based Lentivirus Vectors Expressing Transdominant Rev (2001) (31)
Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. (2000) (31)
Presentation of Tumor Antigens by Dendritic Cells Genetically Modified With Viral and Nonviral Vectors (2006) (30)
Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. (1997) (30)
Transduction of an HLA-DP4–restricted NY-ESO-1–specific TCR into Primary Human CD4+ Lymphocytes (2006) (29)
Correlation of undermethylation of intracisternal A-particle genes with expression in murine plasmacytomas but not in NIH/3T3 embryo fibroblasts. (1984) (28)
Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. (2002) (28)
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma (2011) (28)
Live and let die: a new suicide gene therapy moves to the clinic. (2012) (28)
FAM190A deficiency creates a cell division defect. (2013) (27)
Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. (1995) (27)
Genetic engineering with T cell receptors. (2012) (26)
Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients. (1997) (24)
In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning. (1997) (24)
Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia. (1992) (24)
A Novel Murine T-Cell Receptor Targeting NY-ESO-1 (2014) (24)
Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models (2020) (22)
Identification and characterization of a tumor infiltrating CD56+/CD16− NK cell subset with specificity for pancreatic and prostate cancer cell lines (2010) (22)
Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer (2014) (22)
Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. (1999) (21)
Genetic modification of T cells. (2011) (21)
Genetic Modification of T Cells (2016) (21)
Construction and Pre-Clinical Evaluation of An Anti-CD19 Chimeric Antigen Receptor (2008) (20)
Comparison of retroviral and adeno-associated viral vectors designed to express human clotting factor IX. (1997) (20)
Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system. (1999) (20)
Improved Titer and Gene Transfer by Lentiviral Vectors Using Novel, Small β-Globin Locus Control Region Elements. (2020) (19)
Gene therapy-based treatment for HIV-positive patients with malignancies. (2002) (19)
Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals. (1998) (19)
Gene therapy: lessons learnt from the past decade (1999) (18)
Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells (2015) (18)
High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes. (2003) (18)
Characterization of diverse viral vector preparations, using a simple and rapid whole-virion dot-blot method. (1998) (17)
Estimates of mRNA abundance in the mouse blastocyst based on cDNA library analysis (1989) (17)
Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells (1999) (17)
Abstract LB-175: Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 (2010) (16)
Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. (2002) (16)
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. (2011) (16)
Transcription of intracisternal A-particle genes in mouse myeloma and Ltk- cells (1984) (15)
Genetic strategies to inhibit HIV. (1999) (15)
Gene therapy clinical trials for HIV. (1999) (15)
A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. (2012) (13)
KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma (2013) (12)
Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages. (1998) (12)
Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies. (2014) (12)
In vitro infection of human bone marrow by feline leukemia viruses. (1993) (11)
A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells (2010) (11)
Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation (2011) (10)
Salient Features of Endonuclease Platforms for Therapeutic Genome Editing. (2016) (10)
Murine A type retroviruses promote high levels of gene expression in embryonal carcinoma cells. (1988) (10)
Retroviral Vectors in Human Gene Therapy (1995) (10)
Erratum: Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes (Nature Medicine (1998) 4 (181-186)) (1998) (10)
Faster, cheaper, safer, T-cell engineering. (2013) (9)
Cancer therapy with genetically‐modified T cells for the treatment of melanoma (2012) (9)
Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors. (2014) (8)
Human gene therapy. (1992) (8)
Multiple CTL specificities against autologous HIV-1-infected BLCLs. (1995) (8)
Risky business: target choice in adoptive cell therapy. (2013) (8)
A Novel TGF-β2/Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β2-Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks (2017) (7)
regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer (2009) (7)
Pancreatic cancer (2000) (6)
ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control. (2017) (6)
Gene therapy for HIV infection. (2002) (6)
Expression of Two Murine Gene Families in Transformed Cells and Embryogenesis (1985) (6)
Semliki Forest virus vectors for gene transfer. (2003) (6)
Creating New β-Globin-Expressing Lentiviral Vectors by High-Resolution Mapping of Locus Control Region Enhancer Sequences (2020) (5)
A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances (2015) (5)
Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. (2014) (4)
Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase. (2013) (4)
A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity (2015) (4)
Erratum: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (Cancer Immunol Immunother DOI 10.1007/s00262-011-0977-7) (2011) (4)
Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma (2014) (3)
Inhibition of Histone Lysine Methylation Enhances Expression of Cancer-Testis Genes in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer (2011) (3)
Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment (2020) (3)
The position of the AUG start codon in MFG‐based γ‐retroviral vectors has a dramatic effect on translation‐dependent protein expression (2011) (3)
Local Delivery of lnterleukin-12 using T cells Targeting Vascular Endothelial Growth Factor Receptor-2 Eradicates Multiple Vascularized Tumors in Mice (2012) (3)
B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor (2011) (3)
PCR and other test systems in human gene therapy. (1992) (2)
Abstract 602: A novel TGF-β/IL-12R signal conversion platform that protects CAR T cells from TGF-β-mediated immune suppression and concurrently amplifies effector function (2017) (2)
Post-transcriptional regulation and DNA undermethylation of intracisternal A particle genes in embryonal carcinoma cell lines. (1987) (2)
Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma (2013) (2)
Generation of Natural Killer Cells with Enhanced Function from a CRISPR/Cas12a-Edited Induced Pluripotent Stem Cell Line (2020) (2)
Gene therapy for AIDS (1996) (1)
Abstract 1536: Enhancing CAR T cell activity by linking IL-12 expression to the endogenousPDCD1promoter (2018) (1)
RECENT PROGRESS AND FUTURE DIRECTIONS USING ENGINEERED T CELLS FOR THE TREATMENT OF CANCER (2010) (1)
Anti-viral strategies. (1995) (1)
Erratum to "Sustained Phenotypic Correction of Hemophilia A Mice Following Oncoretroviral-Mediated Expression of a Bioengineered Human Factor VIII Gene in Long-Term Hematopoietic Repopulating Cells". (2005) (1)
Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference (2014) (1)
Abstract 2296: Inhibition of the PI3K/Akt pathway during CAR T cell production results in enhanced efficacy across multiplein vivotumor models (2016) (1)
Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies (2013) (1)
979. Clonal Expansion of a CD8+ T Cell Clone after Retroviral Transduction of Mature T Lymphocytes with the IL-15 Gene (2006) (1)
Prognosis CpG Island Methylator Phenotype – Positive Tumors in the Absence of MLH 1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis (2012) (1)
185. Cloning and Modification of a T-Cell Receptor Gene Targeting Tyrosinase Confers Peptide and HLA Specific Reactivity to Transduced Peripheral Blood Lymphocytes (2009) (1)
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry (2012) (1)
Knockout of CBLB Greatly Enhances Anti-Tumor Activity of CAR T Cells (2018) (1)
Minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system. Production and use. (2002) (1)
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. (2006) (1)
Adoptive immunotherapy with T cells enhanced survival. (2005) (0)
Imaging , Diagnosis , Prognosis CpG Island Methylator Phenotype – Positive Tumors in the Absence of MLH 1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis (2012) (0)
Abstract 3966: Development of a fully-human chimeric antigen receptor against PSCA for the treatment of pancreatic cancer. (2013) (0)
Commentary on “A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors” (2016) (0)
Lymphocytes Mononuclear Cells and Tumor-Infiltrating Reactivity to Nonreactive Peripheral Blood Confers Both High Avidity and Tumor Gene Transfer of Tumor-Reactive TCR (2006) (0)
Comment on Casucci Et Al, Page 3461 (0)
NON‐MYELOABLATIVE ALLOGENEIC TRANSPLANTATION OF GENETICALLY MODIFIED PBSCS FOR HEMATOLOGIC MALIGNANCIES IN HIV + ADULTS.: ABSTRACT 3 (2000) (0)
Targeting Tyrosinase Engineered with a Highly Avid TCR Effective In Vivo Tumor Treatment When Both CD4 and CD8 T Cells Mediate Equally (2010) (0)
Cell Lines Recognize and Kill Diverse Human Tumor with NY-ESO-1 Antigen-Specific TCR Genes Primary Human Lymphocytes Transduced (2005) (0)
Abstract 3504: Generation and optimization of a chimeric antigen receptor against human CD22: A new immunotherapeutic agent for adoptive immunotherapy (2012) (0)
Internal ribosome entry provide retroviral vectors contained (1992) (0)
Abstract 4876: DZNep enhances apoptosis and augments cancer-testis antigen expression mediated by DNA demethylating agents and histone deacetylase inhibitors in lung cancer cells (2010) (0)
Abstract 1672: Tumor educated B cells acquire immune suppressive function and promote tumor growth (2014) (0)
Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma (2015) (0)
Abstract A120: Tumor-educated B cells acquire LAP/TGF-β1 and PD-L1 expression and suppress antitumor immune response (2016) (0)
Adoptive T-cell Therapy (2013) (0)
Differentiation of t-lymphocytes from human umbilical cord blood stem cells cultured In vitro On murine thymic stroma (2000) (0)
Adoptive Cell Transfer and Lymphodepleting Chemotherapy for the Treatment of Metastatic Melanoma (2011) (0)
Exogenous Cytokine Persist Long-Term in the Absence of Cytokine Withdrawal-Induced Apoptosis and with a Codon-Optimized IL-15 Gene Resist Primary Human T Lymphocytes Engineered (2005) (0)
Abstract 4006: Smad6 upregulation provides an alternative mechanism for BMP inactivation in SMAD4 wild type pancreatic cancers. (2013) (0)
Adoptive immunotherapy with enhanced T-lymfocytoverlevelse (2005) (0)
145 Preclinical development of EDIT-201, a multiplexed CRISPR-Cas12a gene edited healthy donor derived NK cells demonstrating improved persistence and resistance to the tumor microenvironment (2020) (0)
CAN-10-0735 Cancer esearch oenvironment and Immunology or-Specific CD 8 + T Cells Expressing Interleukin-12 R dicate Established Cancers in Lymphodepleted Hosts (2010) (0)
Applying cDNA microarray technology to gene therapy (1999) (0)
Stem cells and cancer immunotherapy (2014) (0)
and remain responsive to antigen Interleukin-2-transduced lymphocytes grow in an autocrine fashion (2011) (0)
747. Towards the Clinical Application of BCMA CAR T Cells: The Importance of Reduced Tonic Signaling and Methods to Enhance Memory T Cells (2016) (0)
Boolean immunotherapy: reversal of fortune. (2014) (0)
subsets possess superior traits for adoptive immunotherapy T cells derived from naive rather than memory + Human effector CD8 (2011) (0)
Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma (2011) (0)
767. Genetic Engineering of an Immortal Human CD8+ T Cell Line (2006) (0)
In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope (2008) (0)
Comparison of Anti-HIV-1 Retroviral Vectors and Their Use in a Gene Therapy Trial in Identical Twins (1995) (0)
454. Recognition of Tumor Antigens by In Vitro Developed T Cells from Hematopoietic Stem Cells Retrovirally Transduced with TCR Genes (2006) (0)
Signi fi cance of the Genetic Landscape of Pancreatic Cancer and Implications for Identi fi cation of Potential Long-term Survivors (2012) (0)
Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy (2013) (0)
malignancies in patients with acquired immunodeficiency syndrome modified HLA-matched peripheral blood progenitor cells for hematologic Nonmyeloablative conditioning followed by transplantation of genetically (2013) (0)
retroviral vectors containing sites internal ribosome entry. (1992) (0)
Chimeric T cell receptors, and related materials and methods for using (2007) (0)
high-throughput genotyping A set of canine interrepeat sequence PCR markers for (2015) (0)
186. Phenotypic Correction of Hemophilic Mice Using Hematopoietic Stem Cells Transduced with an MSCV-Based Oncoretroviral Vector (2004) (0)
77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma (2015) (0)
Lines Ability to Recognize and Kill Tumor Cell T Cells with the + Display Provide CD 4 High-Affinity TCRs Generated by Phage Rosenberg and (2007) (0)
GENE THERAPY (1996) (0)
A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma (2015) (0)
A Bicistronic Retroviral Vector Expressing IL-15 and Herpes Simplex Virus Thymidine Kinase for the Transduction of Human T Lymphocytes for Adoptive Cell Transfer Therapies (2013) (0)
TCR with Enhanced Tumor Recognition Selected Murine Residues Endow Human (2010) (0)
Recognition of Melanoma-Associated Antigens gp100 or Mart1/Melan-A in the Context of HLA-A2 by Soluble Single Chain T-Cell Receptor Multimers (93.15) (2007) (0)
Primates Using a Gibbon Ape Leukemia Virus-Derived Retroviral Vector T Lymphocytes in Nonhuman + Efficient In Vivo Marking of Primary CD4 (2013) (0)
DNA technology continues to improve (1989) (0)
Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells (2011) (0)
Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Recapitulates Endogenous CYBB Regulation and Expression. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard A. Morgan?

Richard A. Morgan is affiliated with the following schools:

University of California, Los Angeles
Johns Hopkins University
University of Miami
Duke University

Richard A. Morgan's Academic­Influence.com Rankings

Richard A. Morgan's Degrees

Why Is Richard A. Morgan Influential?

Richard A. Morgan's Published Works

Published Works

What Schools Are Affiliated With Richard A. Morgan?

Richard A. Morgan's AcademicInfluence.com Rankings